Search Results - "Maur, Michela"

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations by Guaitoli, Giorgia, Bertolini, Federica, Bettelli, Stefania, Manfredini, Samantha, Maur, Michela, Trudu, Lucia, Aramini, Beatrice, Masciale, Valentina, Grisendi, Giulia, Dominici, Massimo, Barbieri, Fausto

“…rearrangements are reported in about 1-2% of non-squamous non-small-cell lung cancer (NSCLC). After efficacy of crizotinib was demonstrated, identification of…”
Get full text

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies by Lin, Chia-Chi, Garralda, Elena, Schöffski, Patrick, Hong, David S, Siu, Lillian L, Martin, Miguel, Maur, Michela, Hui, Rina, Soo, Ross A, Chiu, Joanne, Zhang, Tian, Ma, Brigette, Kyi, Chrisann, Tan, Daniel Sw, Cassier, Philippe A, Sarantopoulos, John, Weickhardt, Andrew, Carvajal, Richard D, Spratlin, Jennifer, Esaki, Taito, Rolland, Fréderic, Akerley, Wallace, Deschler-Baier, Barbara, Rispoli, Lawrence, Samant, Tanay S, Chowdhury, Niladri Roy, Gusenleitner, Daniel, Kwak, Eunice L, Askoxylakis, Vasileios, De Braud, Filippo

“…Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This…”
Get full text

A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma by Santoro, Armando, Assenat, Eric, Yau, Thomas, Delord, Jean-Pierre, Maur, Michela, Knox, Jennifer, Cattan, Stephane, Lee, Kyung-Hun, Del Conte, Gianluca, Springfeld, Christoph, Leo, Elisa, Xyrafas, Alexandros, Fairchild, Lauren, Mardjuadi, Feby, Chan, Stephen L.

“…This phase Ib/II trial evaluated the safety and efficacy of capmatinib in combination with spartalizumab or spartalizumab alone in patients with advanced…”
Get full text

Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine by PEROTTI, Antonella, LOCATELLI, Alberta, ALBANELL, Joan, MARSONI, Silvia, CORRADINO, Irene, BERK, Lori, RIVERA, Victor M, HALUSKA, Frank, GIANNI, Luca, SESSA, Cristiana, HESS, Dagmar, VIGANO, Lucia, CAPRI, Giuseppe, MAUR, Michela, CERNY, Thomas, CRESTA, Sara, ROJO, Federico

“…Synergistic/additive cytotoxicity in tumor models and widespread applicability of fluoropyrimidines in solid tumors prompted the study of the combination of…”
Get full text

GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion by Grisendi, Giulia, Annerén, Cecilia, Cafarelli, Luigi, Sternieri, Rita, Veronesi, Elena, Cervo, Gian Luca, Luminari, Stefano, Maur, Michela, Frassoldati, Antonio, Palazzi, Giovanni, Otsuru, Satoru, Bambi, Franco, Paolucci, Paolo, Pierfranco, Conte, Horwitz, Edwin, Dominici, Massimo

“…Abstract Background aims Bone marrow (BM) mesenchymal stromal/stem cells (MSC) are therapeutic tools in regenerative medicine and oncology. MSC isolation is…”
Get full text

Optimised Tumour Sampling and Processing by a Multidisciplinary Approach for an Accurate Diagnosis in Non-Small Cell Lung Cancer by Rossi, Giulio, Bargellini, Irene, Bonifazi, Martina, Camplese, Pierpaolo, Candoli, Piero, Ceron, Loris, Gasparini, Stefano, Granone, Pier Luigi, Grossi, Francesco, Iezzi, Roberto, Marchetti, Antonio, Maur, Michela, Poletti, Venerino, Posa, Alessandro, Trisolini, Rocco, Veltri, Andrea, Zito-Marino, Federica

“…The classification of lung cancer has evolved parallel to the knowledge of its biomolecular features and is implemented by the analysis of specific gene…”
Get full text

Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it by Omarini, Claudia, Maur, Michela, Luppi, Gabriele, Narni, Franco, Luppi, Mario, Dominici, Massimo, Longo, Giuseppe, Piacentini, Federico

“…At the end of January 2020, a novel betacoronavirus, known as severe acute respiratory syndrome coronavirus 2, progressively spread in Italy. Patients with…”
Get full text

Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma by Maur, Michela, Tomasello, Chiara, Frassoldati, Antonio, Dieci, Maria Vittoria, Barbieri, Elena, Conte, Pierfranco

Get full text

Treating cancer with immunotherapy in HIV-positive patients: A challenging reality by Guaitoli, Giorgia, Baldessari, Cinzia, Maur, Michela, Mussini, Cristina, Meschiari, Marianna, Barbieri, Fausto, Cascinu, Stefano, Bertolini, Federica

“…Immunotherapy has widely changed the management of different malignancies. However, efficacy and safety of immune checkpoint inhibitors (ICIs) are not well…”
Get full text

Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence by Aramini, Beatrice, Masciale, Valentina, Grisendi, Giulia, Bertolini, Federica, Maur, Michela, Guaitoli, Giorgia, Chrystel, Isca, Morandi, Uliano, Stella, Franco, Dominici, Massimo, Haider, Khawaja Husnain

“…Emerging evidence suggests that a small subpopulation of cancer stem cells (CSCs) is responsible for initiation, progression, and metastasis cascade in tumors…”
Get full text

Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study by Felip, Enriqueta, de Braud, Filippo G, Maur, Michela, Loong, Herbert H, Shaw, Alice Tsang, Vansteenkiste, Johan F, John, Thomas, Liu, Geoffrey, Lolkema, Martijn P, Selvaggi, Giovanni, Giannone, Vanessa, Cazorla, Pilar, Baum, Jason, Balbin, O Alejandro, Wang, Luojun Victor, Lau, Yvonne Y, Scott, Jeffrey W, Tan, Daniel Shao-Weng

“…Induction of programmed death ligand 1 (PD-L1) expression due to constitutive oncogenic signaling has been reported in NSCLC models harboring echinoderm…”
Get more information

Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study by Curigliano, Giuseppe, Martin, Miguel, Jhaveri, Komal, Beck, J.T., Tortora, Giampaolo, Fazio, Nicola, Maur, Michela, Hubner, Richard A., Lahner, Harald, Donnet, Valerie, Ajipa, Olga, Li, Zheng, Blumenstein, Lars, Andre, Fabrice

“…Combined mTORC1 inhibition with everolimus (EVE) and phosphatidylinositol 3-kinase catalytic subunit p110α blockade with alpelisib (ALP) has demonstrated…”
Get full text

First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations by Janku, Filip, Kim, Tae Min, Iyer, Gopakumar, Spreafico, Anna, Elez, Elena, de Jonge, Maja, Yamamoto, Noboru, van der Wekken, Anthonie J, Ascierto, Paolo Antonio, Maur, Michela, Marmé, Frederik, Kiladjian, Jean-Jacques, Basu, Sumit, Baffert, Fabienne, Buigues, Amparo, Chen, Chi, Cooke, Vesselina, Giorgetti, Elisa, Kim, Jaeyeon, McCarthy, Fiona, Moschetta, Michele, Dummer, Reinhard

“…We investigated naporafenib (LXH254), a pan-RAF kinase inhibitor, with or without spartalizumab, in patients with advanced solid tumors harboring MAPK pathway…”
Get full text

Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR + Advanced Breast Cancer by Tolaney, Sara M, Im, Young-Hyuck, Calvo, Emiliano, Lu, Yen-Shen, Hamilton, Erika, Forero-Torres, Andres, Bachelot, Thomas, Maur, Michela, Fasolo, Angelica, Tiedt, Ralph, Nardi, Lisa, Stammberger, Uz, Abdelhady, Ahmed M, Ruan, Shiling, Lee, Soo Chin

“…Resistance to treatment with endocrine therapy in patients with HR , HER2 advanced breast cancer (ABC) is common and dual inhibition of CDK4/6 and PI3K…”
Get full text

Genomic profiling in advanced NSCLC in Italy: First results of NERoNE (NSCLC Emilia Romagna Next Generation Sequencing Evaluation) project by Bertolini, Federica, Alberti, Giulia, Petracci, Elisabetta, Bettelli, Stefania, Ulivi, Paola, Cravero, Paola, Guaitoli, Giorgia, Zanelli, Francesca, Burgio, Marco Angelo, Andrikou, Kalliopi, Pagano, Maria, Verlicchi, Alberto, Calistri, Daniele, Flospergher, Michele, Mastrodomenico, Luciana, Maur, Michela, Di Emidio, Katia, Dominici, Massimo, Pinto, Carmine, Delmonte, Angelo

“…e21077 Background: The NERoNE Project evaluates the use of Next Generation Sequencing (NGS) in molecular profiling of advanced NSCLC (aNSCLC) patients (pts) in…”
Get full text

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration‐Resistant Prostate Cancer by Agarwal, Neeraj, Machiels, Jean‐Pascal, Suárez, Cristina, Lewis, Nancy, Higgins, Michaela, Wisinski, Kari, Awada, Ahmad, Maur, Michela, Stein, Mark, Hwang, Andy, Mosher, Rebecca, Wasserman, Ernesto, Wu, Gang, Zhang, Hefei, Zieba, Renata, Elmeliegy, Mohamed

“…Lessons Learned Despite evidence for a role for prolactin signaling in breast and prostate tumorigenesis, a prolactin receptor‐binding monoclonal antibody has…”
Get full text

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies by Schöffski, Patrick, Tan, Daniel S W, Martín, Miguel, Ochoa-de-Olza, María, Sarantopoulos, John, Carvajal, Richard D, Kyi, Chrisann, Esaki, Taito, Prawira, Amy, Akerley, Wallace, De Braud, Filippo, Hui, Rina, Zhang, Tian, Soo, Ross A, Maur, Michela, Weickhardt, Andrew, Krauss, Jürgen, Deschler-Baier, Barbara, Lau, Allen, Samant, Tanay S, Longmire, Tyler, Chowdhury, Niladri Roy, Sabatos-Peyton, Catherine A, Patel, Nidhi, Ramesh, Radha, Hu, Tiancen, Carion, Ana, Gusenleitner, Daniel, Yerramilli-Rao, Padmaja, Askoxylakis, Vasileios, Kwak, Eunice L, Hong, David S

“…BackgroundLymphocyte-activation gene 3 (LAG-3) is an inhibitory immunoreceptor that negatively regulates T-cell activation. This paper presents preclinical…”
Get full text

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature by Isca, Chrystel, Piacentini, Federico, Mastrolia, Ilenia, Masciale, Valentina, Caggia, Federica, Toss, Angela, Piombino, Claudia, Moscetti, Luca, Barbolini, Monica, Maur, Michela, Dominici, Massimo, Omarini, Claudia

“…MicroRNAs (miRNA) are small noncoding RNAs that can act as both oncogene and tumor suppressors. Deregulated miRNA expression has been detected in human…”
Get full text

Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: a single institutional retrospective report by Trudu, Lucia, Guaitoli, Giorgia, Bertolini, Federica, Maur, Michela, Santini, Chiara, Papapietro, Vito Roberto, Talerico, Sabrina, Natalizio, Salvatore, Isca, Chrystel, Dominici, Massimo, Barbieri, Fausto

“…: Aims of the study were to explore outcomes and toxicities of chemotherapy-immunotherapy (CT-IT) for patients (pts) with metastatic nonsquamous non-small-cell…”
Get full text

A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer by Bendell, Johanna C., Pelzer, Uwe, Womack, Mark S., Borazanci, Erkut Hasan, Bahary, Nathan, Garrido-Laguna, Ignacio, Maur, Michela, Prater, Tyler, Levy, Donna Elise, Cronier, Damien, Ramage, Sam, Macarulla, Teresa

“…Abstract only TPS524 Background: Olaratumab is a human IgG1 monoclonal antibody that specifically binds human platelet-derived growth factor receptor (PDGFR)-α…”
Get full text